Cargando…

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial

INTRODUCTION: Critically ill patients are predisposed to venous thromboembolism. We hypothesized that higher doses of enoxaparin would improve thromboprophylaxis without increasing the risk of bleeding. Peak anti-factor Xa (anti-Xa) levels of 0.1 to 0.4 IU/ml reflect adequate thromboprophylaxis for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Sian, Zincuk, Aleksander, Larsen, Ulla Lei, Ekstrøm, Claus, Nybo, Mads, Rasmussen, Bjarne, Toft, Palle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057520/ https://www.ncbi.nlm.nih.gov/pubmed/23601744 http://dx.doi.org/10.1186/cc12684

Ejemplares similares

Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial
por: Robinson, Sian, et al.
Publicado: (2010)

A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
por: Robinson, Sian, et al.
Publicado: (2014)

Effective dosage of enoxaparin for intensive care patients
por: Robinson, S, et al.
Publicado: (2013)

Diagnostic value of prehospital arterial blood gas measurements – a randomised controlled trial
por: Zwisler, Stine T., et al.
Publicado: (2019)

Predictors of renal recovery in critically ill patients with AKI: observations from the ongoing FBI clinical trial
por: Robinson, S, et al.
Publicado: (2015)

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment
por: Karaoui, Lamis R., et al.
Publicado: (2018)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial
por: Alavi-Darazam, Ilad, et al.
Publicado: (2022)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial
por: Alalaf, Shahla K, et al.
Publicado: (2015)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Adequate thromboprophylaxis in critically ill patients
por: Levi, Marcel
Publicado: (2010)

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
por: Barco, Stefano, et al.
Publicado: (2022)

Thromboprophylaxis with unilateral pneumatic device led to less edema and blood loss compared to enoxaparin after knee arthroplasty: randomized trial
por: Maradei-Pereira, João Alberto Ramos, et al.
Publicado: (2022)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
por: Rosencher, Nadia, et al.
Publicado: (2012)

Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study
por: Albani, Filippo, et al.
Publicado: (2020)

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients
por: Zufferey, Paul Jacques, et al.
Publicado: (2021)

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
por: MacDougall, Kira, et al.
Publicado: (2020)

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
por: Gómez-Outes, Antonio, et al.
Publicado: (2012)

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)
por: Longo de Oliveira, André Luiz Malavasi, et al.
Publicado: (2022)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting
por: Zindel, Sonja, et al.
Publicado: (2012)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection
por: Kummer, R.L., et al.
Publicado: (2021)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Congenital diaphragmatic hernia presenting with symptoms within the first day of life; outcomes from a non-ECMO centre in Denmark
por: Larsen, Ulla Lei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6mo90n7o0nmedf7kjflh703k1p